At BTG we are focused on bringing to market innovative products in specialist areas of medicine to better serve doctors and patients. Our growing portfolio of Interventional Medicine products is designed to advance the treatment of liver tumours, advanced emphysema, severe blood clots, and varicose veins, while our Specialty Pharmaceuticals portfolio offers antidotes that alleviate toxicity and treat rare conditions. Healthcare is constantly evolving – so BTG never stands still. Inspired by a deep understanding of our customers’ needs, we’re working to meaningfully improve the lives of patients and their healthcare experience. Our competitive advantage is our dedication to finding smart, often unconventional solutions to complex medical problems. Many of our products combine medicines, device technology and new techniques in order to deliver more targeted treatments. We also invest in the clinical evidence that helps demonstrate the value of our products to doctors, patients, and healthcare systems. Doing what’s right for patients is what gets us to work in the morning. It’s part of our DNA. By staying true to this principle and our values, we’ve earned a strong reputation for the quality of our products and our commitment to innovation. Whether developed in our own labs or in partnership with clinicians, academics, and other companies, we believe passionately that medical innovation has the power to improve human health. Imagine where we can go.
Company Growth (employees)
London, GB
Size (employees)
1,355 (est)+15%
BTG was founded in 1948 and is headquartered in London, GB

BTG Office Locations

BTG has offices in London, Alzenau, Conshohocken, Brentwood and in 4 other locations
London, GB (HQ)
5 Fleet Pl
Neihu District, TW
4D, No. 66, Sec. 1, Neihu Road Neihu District Taipei City Taiwan
Hong Kong, HK
Room 2905, 29/Floor, ACE Tower, Windsor House, 311 Gloucester Road Causeway Bay Hong Kong
Rosedale, AU
RSD Turretfield RC, 129 Holland Road
Ottawa, CA
200 11 Hines Rd
Brentwood, US
405 5214 Maryland Way

BTG Data and Metrics

BTG Financial Metrics

BTG's revenue was reported to be £447.5 m in FY, 2016 which is a 22% increase from the previous period.

Revenue (FY, 2016)

447.5 m

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

306.7 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

60.5 m

Market capitalization (24-Jul-2017)

2.6 b

Closing share price (24-Jul-2017)


Cash (31-Mar-2016)

140.4 m
BTG's current market capitalization is £2.6 b.
GBPFY, 2014FY, 2015FY, 2016


290.5 m367.8 m447.5 m

Revenue growth, %


Cost of goods sold

95 m114.7 m140.8 m

Gross profit

195.5 m253.1 m306.7 m

Gross profit Margin, %


Operating expense total

168.2 m218.2 m250.2 m

Pre tax profit

33.3 m26.7 m57.5 m

Net Income

24.3 m33.6 m60.5 m
GBPFY, 2014FY, 2015FY, 2016


38.2 m73.8 m140.4 m

Current Assets

146.2 m207.6 m297.5 m


44 m56.6 m64.2 m


521.5 m781.7 m787.1 m

Total Assets

711.7 m1 b1.1 b

Accounts Payable

14 m10.8 m16 m

Current Liabilities

87.8 m115.6 m125 m

Total Liabilities

181.3 m287.3 m301.1 m

Retained Earnings

24.3 m33.6 m60.5 m

Total Equity

530.4 m758.6 m847.7 m

Financial Leverage

1.3 x1.4 x1.4 x
GBPFY, 2014FY, 2015FY, 2016

Cash From Operating Activities

48.5 m47.5 m95.6 m

Cash From Financing Activities

102.7 m146.2 m

Income Taxes Paid

(9 m)6.9 m3 m
GBPY, 2016


453.9 k

Financial Leverage

1.4 x

BTG Market Value History

BTG Job Categories

BTG Median Salaries

Source: 13 public H-1B filings from BTG

Traffic Overview of BTG

BTG Online and Social Media Presence

BTG News and Updates

UPDATE 2-BTG Pactual misses profit view, in sign asset sales biting

SAO PAULO, Aug 9 (Reuters) - Grupo BTG Pactual SA on Tuesday missed second-quarter profit estimates for the first time in almost two years, as downsizing efforts by Latin America's largest independent investment bank curbed trading and money management income.

BTG Pactual's Swiss unit BSI posts second-quarter $6.4 bln outflows

SAO PAULO/ZURICH, Aug 9 (Reuters) - BSI SA, a Swiss private bank in the process of being bought by rival EFG International AG, saw net second-quarter new money outflows of 6.3 billion Swiss francs ($6.4 billion) amid sanctions over business ties to a scandal-hit Malaysian government fund.

Zell's Equity International to invest $125 mln in BTG Pactual's Estapar

SAO PAULO, Aug 8 (Reuters) - Sam Zell's fund Equity International is investing $125 million to get an undisclosed stake in Brazilian parking lot operator Estapar Participações SA, which is controlled by investment bank Grupo BTG Pactual, the companies said in a statement Monday.

BTG Company Life and Culture

You may also be interested in